
Time for a public inquiry: RCP report reveals scale of Coventry cancer care failings
10 min readPublished:

Alongside current and former patients treated at University Hospitals Coventry and Warwickshire NHS Trust (UHCW) we’re calling for a full, independent public inquiry into the cancer care failings identified in a Royal College of Physicians (RCP) report published today.
The report raises serious and systemic concerns regarding the treatment and care of brain cancer patients in the Trusts neuro-oncology service, centred on the prolonged use of a chemotherapy regime that patients say left them with life-changing (and in some cases, irreversible) harm.
The regime was overseen by retired neuro-oncologist Ian Brown who has since left the Trust. Many of these patients have suffered devastating harm, including infertility, secondary cancers, chronic fatigue, loss of career and profound psychological distress.
The full report sets out failings across multiple levels of care at the Trust and raises serious questions about clinical practice, oversight, governance and patient safety.
Our medical & clinical negligence team is representing over 45 patients and believes that many more people could still be affected. The report’s findings add further weight to calls for a full, independent public inquiry to establish how these failings were allowed to happen, whether other patients have been affected and what action is needed to prevent similar failures in the future.
The full RCP findings
The report exposes systemic failings across UHCW’s neuro-oncology service, including concerns around potential misdiagnoses, informed consent and serious patient harm.
The review carried out by the RCP found extended treatment being given without evidence base. It raises concerns around consent in all of the cases that it reviewed. It also highlights incorrect or insecure diagnoses as well as serious failures of clinical oversight.
Its recommendations are that every living patient treated with more than 12 cycles of the chemotherapy drug temozolomide (TMZ) should have their case independently reviewed, while recognising that a large cohort of deceased patients who received the same non-standard treatment may also have come to harm.
Statement from Fiona Tinsley, Partner and Head of Medical Negligence & Serious Injury:
For the patients and families we represent, these findings confirm many of the concerns they have been fighting to have acknowledged since coming forward. Some patients were led to believe that stopping chemotherapy would be harmful, despite the RCP finding that extended treatment had no evidence base.
These treatment failings didn’t happen in isolation — they were enabled by repeated failures across the service for around two decades. The RCP’s findings identified that pharmacies did not provide the level of clinical challenge expected, multidisciplinary working was inadequate and governance arrangements that should have protected patients were described as wholly ineffective. There were multiple opportunities for intervention, but the practice was allowed to continue.
Taken together, these findings point to systemic failures in the care and oversight of these patients. What is particularly difficult to accept is that this was not a problem hidden from view. The report suggests that many within the Trust were aware that patients were being kept on prolonged, non-standard chemotherapy, yet responsibility for challenging it was repeatedly assumed to sit with someone else.
Behind every finding in this report is a person whose life has been changed. People spent years enduring debilitating treatment because they were told that they had no alternative. Some lost careers, fertility and years of normal family life. Others have been left living with the possibility of serious long-term complications. Some have died while waiting for answers.
We welcome the fact that these failings have finally been independently recognised but recognition alone is nowhere near enough.
The RCP’s report examined just 20 patients’ cases. We represent more than 45 people with serious concerns about their care and we know that the issues stretch back more than two decades. The RCP itself has even indicated that its concerns extend beyond the patients it reviewed. That raises an obvious and deeply troubling question about how much wider these failings may go.
This report cannot be the end point.
We are calling on the Health Secretary to establish a full, independent public inquiry, with patients and their families at its heart. We need to establish how these failures were allowed to become embedded, why the safeguards designed to protect patients did not work, who had opportunities to intervene and how many more people may have been affected.
Patients have already spent too long fighting for answers. They should not now have to fight to make sure the full truth comes out.
Timeline of the Coventry cancer care investigation
2026
In June, the Trust admitted liability. This was the first time that the Trust formally acknowledged wrongdoing in relation to the scandal.
In September, an interim RCP letter (dated April) found patient “betrayal” and serious failures in UHCW’s brain tumour treatment. Its findings echo concerns raised by patients and families over recent years and raise serious questions about how these practices were allowed to continue.
Of the twenty cases reviewed in the interim, fifteen were judged to have been unsatisfactory overall. Four required improvements in both clinical and organisational care and one required improvement in clinical care. Not one case was identified as demonstrating good practice.
2025
We worked with media (in particular BBC West Midlands) to campaign for an internal patient safety review on the prolonged use of the chemotherapy drug temozolomide (TMZ) within its neuro-oncology service. It was eventually conducted by UHCW covering the period between 2017 and Ian Brown’s retirement in 2023. Following the significant media coverage, more patients came forward.
Responses to Freedom of Information requests that we submitted show that UHCW spent more than £3.6m on temozolomide between 2007 and 2024. This is more than ten times that of comparable NHS hospitals.
2024
Medical guidance states that temozolomide — which carries severe side effects including extreme fatigue, confusion, sickness and seizures — should be used over a period of six months (and a maximum of 12 months). Our investigation uncovered that patients had been routinely prescribed the drug for several years and in many cases for more than a decade.
Further investigation by our lawyers identified that that numerous patients under the care of Ian Brown had been exposed to prolonged and what they say, in some cases, was unnecessary use of the chemotherapy drug temozolomide over the past two decades. These cases specifically involved individuals with brain and spinal tumours.
Ian Brown retired from University Hospitals Coventry and Warwickshire after working there since the 1990s. Following his retirement, new oncologists reviewing his casework stopped long-term chemotherapy and moved patients to radiological and clinical surveillance, raising concerns about initial diagnoses and courses of treatment administered.
Client voices & stories
Many of our clients have shared their stories, demonstrating the impact that the unnecessary and prolonged treatment has had on their lives.
Becky’s story
At age just 21, Becky was referred to Ian Brown who, she says, told her that without treatment she had six to 12 months to live. Investigations since have concluded she initially misdiagnosed and that, rather than a brain tumour, her diagnosis was most likely to be tumefactive demyelination. The review concluded that she received over 100 cycles of TMZ chemotherapy. Becky’s story of misdiagnosis hit headlines around the world including Europe, America, the Middle East, Africa, Latin America and Asia.
She said about the report: "For years, I questioned why I was still being given chemotherapy when my scans were stable, but I was repeatedly told that without it I would die. Seeing the RCP independently confirm serious failings is validating, although it is incredibly painful to see how many opportunities there were to protect us. I welcome the recommendation that my case, alongside those of every living patient who received more than 12 cycles, should be independently reviewed. I now need a full and honest explanation of what happened to me.
This has shaped my entire adult life. I lost career opportunities, family moments and years to treatment and the constant fear that I was going to die. The report cannot give me that time back, but an independent review may finally provide the answers and accountability I have been fighting for — and help ensure no other patient has to fight this hard to be heard.”
Lucy’s story
After first experiencing seizures in 2012, Lucy was diagnosed with a low-grade brain tumour. After multiple surgeries and MRI scans, her condition was stable. Three years later it was found that the tumour had changed to a more aggressive form and then referred to Ian Brown. Despite local, national and international guidelines, Lucy was prescribed 75 cycles of TMZ across seven years — long after her scans showed no evidence of progression.
David’s story
In 2016, David Bown experienced seizures which led to him being diagnosed with a low-grade brain tumour. He was referred to neuro-oncology, treated as though he had an aggressive, high-grade disease and was prescribed TMZ for eight years. Independent experts have since concluded that the prolonged chemotherapy exposed David to unnecessary risks including increased chances of secondary blood cancers.
Stephen Bown, David’s father, said: “What has happened to David has been devastating. Before all of this, he was working full-time, playing football, coaching and managing an under-9s football team and living his own life. His condition has now deteriorated to the point where he can no longer speak clearly and he depends on us completely. David can’t tell people himself what this has done to him anymore, so as his dad I have to do that for him.
These findings finally recognise the seriousness of what happened to patients like David, but there are still so many questions about how it was allowed to happen. I am relieved that David’s case will be one of those recommended for an independent review because we need someone to look properly at the whole of his care and explain how so many opportunities to protect him were missed.
We cannot change what has happened to David, but we can make sure the truth comes out. He deserves those answers, and so do all the other patients and families who have been affected.”
Anne’s story
Anne Wilkinson has been sharing her husband's story since he died in November 2012. Trevor was in his early 70s when he underwent surgery elsewhere before being referred to UHCW for treatment. Anne says that he experienced adverse effects from TMZ from the outset. Despite his reaction to the medication, there was no further review from the consultant overseeing his care — and his treatment continued.
Andrew’s story
Andrew spent 13 years receiving chemotherapy for what he thought was an aggressive spinal tumour. He spoke to the BBC about his devastation upon being told that his cancer was low-level and the treatment was unnecessary. His incorrect diagnosis at age 19 led to isolation, depression and other health issues.
Seeking answers & accountability
There are likely many more people out there with a similar story. Our chemotherapy negligence specialists Fiona Tinsley and Becky Addison act for a significant number of patients and families affected by concerns surrounding prolonged TMZ treatment at UHCW.
Many of these clients were seeking answers long before the review was commissioned. While its findings provide important confirmation that their concerns were justified, they also raise further questions:
- How were these practices allowed to continue for so long without challenge?
- If concerns were known, did anyone try to intervene?
- Were the hospital’s whistleblowing procedures sufficient to enable staff to speak up?
If you or a loved one received long-term temozolomide chemotherapy at UHCW, were advised to continue treatment for many years, were later informed that the diagnosis may have changed or have questions or concerns about whether the treatment was necessary and properly explained, we may be able to help.
You can get in touch with Becky and Fiona directly or call us on 0333 004 4488, send an email to medneg@brabners.com or complete our contact form.
We’re here to
Make the difference
Trusted guidance is just a call, email or message away. With hundreds of nationally recognised experts, get in touch today to find out how we can help.
Loading form...
Related insights

Brabners backs ambition with landmark Legal Services T Level sponsorship & youth bursary investment
We’ve made a major commitment to technical education and social mobility, becoming the UK’s first founding employer sponsor of a Legal Services T Level.

Brabners appoints Social Impact Manager following B Corp recertification
Freya Grummit will lead the development and delivery of our community initiatives and social and governance (ESG) priorities.












